Brandi Hilder

1.7k total citations · 2 hit papers
43 papers, 978 citations indexed

About

Brandi Hilder is a scholar working on Hematology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Brandi Hilder has authored 43 papers receiving a total of 978 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Hematology, 21 papers in Radiology, Nuclear Medicine and Imaging and 19 papers in Molecular Biology. Recurrent topics in Brandi Hilder's work include Multiple Myeloma Research and Treatments (41 papers), Monoclonal and Polyclonal Antibodies Research (21 papers) and Protein Degradation and Inhibitors (15 papers). Brandi Hilder is often cited by papers focused on Multiple Myeloma Research and Treatments (41 papers), Monoclonal and Polyclonal Antibodies Research (21 papers) and Protein Degradation and Inhibitors (15 papers). Brandi Hilder collaborates with scholars based in United States, Netherlands and Spain. Brandi Hilder's co-authors include Niels W.C.J. van de Donk, Paula Rodríguez‐Otero, Monique C. Minnema, Ajai Chari, María‐Victoria Mateos, Raluca Verona, Amrita Krishnan, Suzette Girgis, Albert Oriol and Jeffery S. Russell and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Brandi Hilder

40 papers receiving 963 citations

Hit Papers

Talquetamab, a T-Cell–Red... 2022 2026 2023 2024 2022 2024 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
    2022 350 citations Ajai Chari, Monique C. Minnema et al. profile →
  2. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
    2024 51 citations Paula Rodríguez‐Otero, Niels W.C.J. van de Donk et al. Blood Cancer Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brandi Hilder United States 16 674 593 517 295 154 43 978
Sandy W. Wong United States 20 583 0.9× 683 1.2× 593 1.1× 159 0.5× 164 1.1× 86 1.1k
Homer Adams United States 10 401 0.6× 401 0.7× 249 0.5× 195 0.7× 237 1.5× 25 713
Kimberly H. Harrington United States 11 307 0.5× 492 0.8× 343 0.7× 254 0.9× 206 1.3× 17 807
Myo Htut United States 15 484 0.7× 777 1.3× 621 1.2× 57 0.2× 206 1.3× 48 1.0k
Lijie Xing China 14 364 0.5× 393 0.7× 336 0.6× 136 0.5× 176 1.1× 49 669
Tengteng Yu China 13 340 0.5× 330 0.6× 280 0.5× 123 0.4× 142 0.9× 44 555
Daniëlle C.H. Jacobs Netherlands 4 562 0.8× 514 0.9× 366 0.7× 298 1.0× 206 1.3× 9 951
Ying-Ming Jou United States 6 349 0.5× 439 0.7× 353 0.7× 35 0.1× 60 0.4× 8 631
Daniel Lebovic United States 14 557 0.8× 427 0.7× 712 1.4× 65 0.2× 70 0.5× 41 1.0k

Countries citing papers authored by Brandi Hilder

Since Specialization
Citations

This map shows the geographic impact of Brandi Hilder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brandi Hilder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brandi Hilder more than expected).

Fields of papers citing papers by Brandi Hilder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brandi Hilder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brandi Hilder. The network helps show where Brandi Hilder may publish in the future.

Co-authorship network of co-authors of Brandi Hilder

This figure shows the co-authorship network connecting the top 25 collaborators of Brandi Hilder. A scholar is included among the top collaborators of Brandi Hilder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brandi Hilder. Brandi Hilder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Rasche, Leo, Carolina Schinke, Cyrille Touzeau, et al.. (2024). Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S240–S240. 5 indexed citations
3.
Schinke, Carolina, Cyrille Touzeau, Monique C. Minnema, et al.. (2024). P-098 Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S99–S99.
4.
Morillo, Daniel, Carmen Martínez Chamorro, Luciano J. Costa, et al.. (2024). P-058 Cytokine Release Syndrome in Patients Receiving Alternative Step-Up Doses of Talquetamab for Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S74–S75. 1 indexed citations
5.
Rasche, Leo, Carolina Schinke, Cyrille Touzeau, et al.. (2024). MM-492 Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S561–S562. 9 indexed citations
6.
Rodríguez‐Otero, Paula, Niels W.C.J. van de Donk, Kodandaram Pillarisetti, et al.. (2024). GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer Journal. 14(1). 24–24. 51 indexed citations breakdown →
7.
Krishnan, Amrita, Luciano J. Costa, Carolina Schinke, et al.. (2023). P-023 Talquetamab, a G protein–coupled receptor family C group 5 member D × CD3 bispecific antibody, in relapsed/refractory multiple myeloma: efficacy and safety of patient subgroups from monumenTAL-1. Clinical Lymphoma Myeloma & Leukemia. 23. S45–S46. 5 indexed citations
8.
9.
Chari, Ajai, Jo Caers, Luciano J. Costa, et al.. (2023). Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma. Future Oncology. 19(27). 1825–1842. 2 indexed citations
10.
Chari, Ajai, Albert Oriol, Amrita Krishnan, et al.. (2023). Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study. Blood. 142(Supplement 1). 1010–1010. 29 indexed citations
11.
Girgis, Suzette, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.. (2022). Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma. Blood Advances. 7(4). 644–648. 30 indexed citations
12.
13.
Girgis, Suzette, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.. (2021). P-001: Modulation of soluble B-cell maturation antigen levels in patients with relapsed and/or refractory multiple myeloma after treatment with teclistamab and talquetamab. Clinical Lymphoma Myeloma & Leukemia. 21. S39–S40. 1 indexed citations
14.
15.
Shah, Jatin J., Jonathan L. Kaufman, Jeffrey A. Zonder, et al.. (2017). A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma. Cancer. 123(23). 4617–4630. 48 indexed citations
16.
Chari, Ajai, Myo Htut, Jeffrey A. Zonder, et al.. (2016). A phase 1 dose‐escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma. Cancer. 122(21). 3327–3335. 33 indexed citations
17.
Lonial, Sagar, Michel Delforge, Hermann Einsele, et al.. (2015). The AfFIRM Study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma.. Journal of Clinical Oncology. 33(15_suppl). TPS8613–TPS8613. 2 indexed citations
18.
Shah, Jatin J., Donna M. Weber, Sheeba K. Thomas, et al.. (2012). Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood. 120(21). 4082–4082. 26 indexed citations
19.
20.
Shah, Jatin J., Jeffrey A. Zonder, Adam D. Cohen, et al.. (2011). ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study. Blood. 118(21). 1860–1860. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sandy W. Wong Breakdown of academic impact, for papers by Homer Adams Breakdown of academic impact, for papers by Kimberly H. Harrington Breakdown of academic impact, for papers by Myo Htut Breakdown of academic impact, for papers by Lijie Xing Breakdown of academic impact, for papers by Tengteng Yu Breakdown of academic impact, for papers by Daniëlle C.H. Jacobs Breakdown of academic impact, for papers by Ying-Ming Jou Breakdown of academic impact, for papers by Daniel Lebovic
Rankless by CCL
2026